Supreme Court Won’t Inoculate GSK In Hatch-Waxman Safe Harbor Case; Momenta May Have Better Shot
This article was originally published in The Pink Sheet Daily
Executive Summary
The high court also denied petitions seeking review of Otsuka’s Abilify patent and patents covering Cephalon’s Amrix; Supreme Court to hear oral arguments in generic preemption and “pay-for-delay” cases in March.